<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052684</url>
  </required_header>
  <id_info>
    <org_study_id>P02-CLN-019(BR)</org_study_id>
    <nct_id>NCT05052684</nct_id>
  </id_info>
  <brief_title>The Leaflex™ Brazilian Standalone Study</brief_title>
  <official_title>The Leaflex™ Brazilian Standalone Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pi-cardia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pi-cardia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, single-arm study aimed to demonstrate safety and performance of&#xD;
      the Leaflex™ Performer in the treatment of symptomatic severe aortic stenosis.&#xD;
&#xD;
      Subjects will be seen at pre- and post procedure, discharge, 30 days and at 3, 6, 9 and 12&#xD;
      months post procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in aortic valve area</measure>
    <time_frame>Baseline and up to 3 days post procedure</time_frame>
    <description>Assessed by echo Assessed by echo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause mortality and all-cause stroke (VARC 2)</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of worsening of aortic regurgitation</measure>
    <time_frame>Baseline and 30 days post procedure</time_frame>
    <description>By more than 1 grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device related adverse events</measure>
    <time_frame>Up to 12 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk test</measure>
    <time_frame>Baseline, 1, 6 and 12 months post procedure</time_frame>
    <description>Distance (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline, 1, 6 and 12 months post procedure</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline, 1, 6 and 12 months post procedure</time_frame>
    <description>EuroQol- 5 Dimension (EQ5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aortic valve area</measure>
    <time_frame>Baseline, up to 3 days, 30 days, 3, 6, 9 and 12 months post procedure</time_frame>
    <description>Assessed by echo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pressure gradients</measure>
    <time_frame>Baseline, up to 3 days, 30 days, 3, 6, 9 and 12 months post procedure</time_frame>
    <description>Assessed by echo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pressure gradients</measure>
    <time_frame>Pre-treatment, immediately post treatment (during procedure)</time_frame>
    <description>Measured invasively</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Leaflex™ Performer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Leaflex™ Performer</intervention_name>
    <description>A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.</description>
    <arm_group_label>Leaflex™ Performer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with symptomatic, severe aortic stenosis who are not recommended by the heart&#xD;
             team for immediate treatment with surgical or transcatheter aortic valve replacement.&#xD;
&#xD;
          -  Patient is willing to comply with scheduled visits and tests and is able and willing&#xD;
             to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe aortic regurgitation.&#xD;
&#xD;
          -  Anatomic contraindications.&#xD;
&#xD;
          -  Coronary, carotid, or vertebral artery disease that, in the opinion of the heart team,&#xD;
             should be treated; or treatment of coronary artery disease ≤ 1 month prior to index&#xD;
             procedure.&#xD;
&#xD;
          -  Aortic balloon valvuloplasty ≤ 3 months prior to index procedure.&#xD;
&#xD;
          -  Stroke ≤ 12 months prior to index procedure.&#xD;
&#xD;
          -  History of a myocardial infarction ≤ 6 weeks prior to index procedure.&#xD;
&#xD;
          -  Patients with clinically significant abnormality in cell blood count, history of&#xD;
             bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Hemodynamic instability.&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy with obstruction.&#xD;
&#xD;
          -  Left ventricle ejection fraction &lt;30%.&#xD;
&#xD;
          -  Ongoing severe infection, including endocarditis, or sepsis.&#xD;
&#xD;
          -  Life expectancy ≤ 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Merav Gat</last_name>
    <phone>+97289484800</phone>
    <email>merav@pi-cardia.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto do Coração FMUSP Centro de Pesquisa</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre Abizaid, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

